Argentina · Delayed Price · Currency is ARS Bioceres Crop Solutions Statistics
Total Valuation
BCBA:BIOX has a market cap or net worth of ARS 154.45 billion. The enterprise value is 553.32 billion.
| Market Cap | 154.45B |
| Enterprise Value | 553.32B |
Important Dates
The last earnings date was Monday, September 8, 2025.
| Earnings Date | Sep 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.45% |
| Shares Change (QoQ) | +0.66% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 37.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.39 |
| PB Ratio | 0.38 |
| P/TBV Ratio | 8.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.96 |
| EV / Sales | 1.13 |
| EV / EBITDA | 27.20 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.79 |
| Debt / EBITDA | 18.60 |
| Debt / FCF | n/a |
| Interest Coverage | -0.12 |
Financial Efficiency
Return on equity (ROE) is -15.90% and return on invested capital (ROIC) is -0.27%.
| Return on Equity (ROE) | -15.90% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -0.27% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BCBA:BIOX has paid 1.55 billion in taxes.
| Income Tax | 1.55B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -73.57% |
| 50-Day Moving Average | 4,067.75 |
| 200-Day Moving Average | 5,762.74 |
| Relative Strength Index (RSI) | 23.14 |
| Average Volume (20 Days) | 75,214 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.95 |
Income Statement
In the last 12 months, BCBA:BIOX had revenue of ARS 397.19 billion and -61.73 billion in losses. Loss per share was -976.74.
| Revenue | 397.19B |
| Gross Profit | 155.16B |
| Operating Income | -3.22B |
| Pretax Income | -64.23B |
| Net Income | -61.73B |
| EBITDA | 17.51B |
| EBIT | -3.22B |
| Loss Per Share | -976.74 |
Balance Sheet
The company has 46.89 billion in cash and 325.70 billion in debt, giving a net cash position of -278.81 billion.
| Cash & Cash Equivalents | 46.89B |
| Total Debt | 325.70B |
| Net Cash | -278.81B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 411.11B |
| Book Value Per Share | 5,861.47 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 39.06%, with operating and profit margins of -0.81% and -15.54%.
| Gross Margin | 39.06% |
| Operating Margin | -0.81% |
| Pretax Margin | -16.17% |
| Profit Margin | -15.54% |
| EBITDA Margin | 4.41% |
| EBIT Margin | -0.81% |
| FCF Margin | n/a |
Dividends & Yields
BCBA:BIOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.45% |
| Shareholder Yield | n/a |
| Earnings Yield | -39.97% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 24, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Jan 24, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |